A retrospective study of intravenous pentamidine for PCP prophylaxis in adult patients with hematological malignancies – its utility during respiratory virus pandemics
In Haematology, prophylaxis for Pneumocystis jirovecii pneumonia (PCP) is recommended for patients undergoing hematopoietic stem cell transplantation (HSCT) and in selected categories of intensive chemotherapy for hematological malignancies (HM) [1]. Trimethoprim –sulfamethoxazole (TMP-SMX) is the recommended first-line agent, but its use is not straightforward, as it can be associated with myelosuppression and elevation of potassium and creatinine [2]. Furthermore, many patients have a sulfa allergy, and some are G6PD (glucose-6-phosphate dehydrogenase) d eficient [3].
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Yi Xin Liew, Aloysius Yew Leng Ho, Gee Chuan Wong, Shimin Jasmine Chung, Thuan Tong Tan, Ban Hock Tan Tags: Short Communication Source Type: research
More News: Allergy | Allergy & Immunology | Bactrim | Cancer & Oncology | Chemotherapy | G6PD | Hematology | Infectious Diseases | Pandemics | Pneumonia | Potassium | Respiratory Medicine | Stem Cell Therapy | Stem Cells | Study | Sulfamethoxazole | Transplants | Trimethoprim